Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse®) with its single active ingredients diclofenac and orphenadrine: A placebo-controlled study using laser-induced somatosensory-evoked potentials from capsaicin-induced hyperalgesic human skin

Drugs in R and D

Volumn 6, Issue 4, 2005, Pages 189-199

  Schaffler, Klaus ^a   Reitmeir, Peter ^b   Gschanes, Andrea ^a   Eggenreich, Udo ^a  

^a Human Pharmacodynamic Research   (Germany)

^b CIS Services ^*

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; DICLOFENAC; NEODOLPASSE; ORPHENADRINE CITRATE; PLACEBO;

ADULT; ANALGESIA; ARTICLE; CARBON DIOXIDE LASER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ERYTHEMA; EVOKED SOMATOSENSORY RESPONSE; FATIGUE; FEMALE; HEADACHE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; HYPERALGESIA; INJECTION SITE REACTION; MALE; NEUROGENIC INFLAMMATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALGESICS; CAPSAICIN; CROSS-OVER STUDIES; DICLOFENAC; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EVOKED POTENTIALS, SOMATOSENSORY; FEMALE; HUMANS; HYPERALGESIA; INFUSIONS, INTRAVENOUS; LASERS; MALE; MIDDLE AGED; ORPHENADRINE; PAIN;

EID: 22244474308     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200506040-00001     Document Type: Article

References (34)

1. Menasse R, Hedwall PR, Kraetz J, et al. Pharmacological properties of diclofenac sodium and its metabolites. Scand J Rheumatol Suppl 1978; 22: 5-16
2. Ku EC, Lee W, Kothari HV, et al. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med 1986; 80: 18-23
3. Todd PA, Sorkin EM. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988; 35: 244-85
4. Jurna I, Brune K. Central effect of the non-steroid anti-inflammatory agents, indomethacin, ibuprofen, and diclofenac, determined in C fibre-evoked activity in single neurones of the rat thalamus. Pain 1990; 41: 71-80
5. Bijlsma UG, Harms AF, Funcke ABH, et al. The pharmacology of β-dimethylaminoethyl-2-methylbenzhydrylether hydrochloride. Arch Int Pharmacodyn Ther 1956; 1: 332-68
6. Ginzel KH. The blockade of reticular and spinal facilitation of motor function by orphenadrine. J Pharmacol Exp Ther 1966; 154: 128-41
7. Onuaguluchi G, Lewis JJ. Some aspects of the pharmacology of orphenadrine. J Pharm Pharmacol 1963; 15: 329-36
8. Smith CM. Relaxation of decerebrate rigidity by orphenadrine. Proc Soc Exp Biol Med 1964; 116: 75-6
9. Steinbrecher W. Myotonolyse durch Orphenadrincitrat. Arzneimittel Forschung 1966; 16: 147-53
10. Hunskaar S, Donell D. Clinical and pharmacological review of the efficacy of orphenadrine and its combination with paracetamol in painful conditions. J Int Med Res 1991; 19: 71-87
11. Schaffler K, Reitmeir P. Analgesic effects of low-dose intravenous orphenadrine in the state of capsaicin hyperalgesia: a randomized, placebo-controlled, double-blind cross-over study: using laser somatosensory evoked potentials obtained from capsaicin-irritated skin in healthy volunteer. Arzneimittel Forschung 2004; 54: 673-9
12. Winter L, Post A. Analgesic combinations with orphenadrine in oral post surgical pain. J Int Med Res 1979; 7: 240-6
13. Raffa RB. Antihistamines as analgesics. J Clin Pharm Ther 2001; 26: 81-5
14. Olsen UB, Eltorp CT, Ingvardsen BK, et al. ReN 1869, a novel tricyclic antihistamine, is active against neurogenic pain and inflammation. Eur J Pharmacol 2002; 435: 43-57
15. Jones B, Kenward MG. Design and analysis of cross-over trials. London: Chapman and Hall, 1989
16. Schaffler K, Wauschkuhn CH, Gierend M. Analgesic potency of a new anticonvulsant drug versus acetylsalicylic acid via laser somatosensory evoked potentials: randomised placebo-controlled double blind (5-way) crossover study. Arzneimittel Forschung 1991; 41: 427-35
17. Schaffler K, Seibel K, Thomsen M, et al. Effect of the new H1-antagonist ReN1869 on capsaicin-induced hyperalgesia in human skin/Human phase-I trial using somatosensory evoked potentials induced by a CO2 laser. Arzneimittel Forschung 2004; 54: 187-91
18. Schaffler K, Wauschkuhn CH, Brunnauer H, et al. Evaluation of the local anaesthetic activity of dimethindene maleate by means of laser algesimetry in healthy volunteers. Arzneimittel Forschung 1992; 42: 1332-5
19. Schaffler K, Medert G. The analgesic, anti-inflammatory profile of dexketoprofen trometamol (vs tramadol). Schmerz 1998; 12 (S1): 69-70
20. 2 laser stimuli causing pain. Exp Brain Res 1984; 55: 158-66
21. Putt M, Chinchilli VM. A mixed effects model for the analysis of repeated measures cross-over studies. Stat Med 1999; 18: 3037-58
22. Zecca L, Ferrario P, Costi P. Determination of diclofenac and its metabolites in plasma and cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1991; 567: 425-32
23. Valtonen EJ. A controlled clinical trial of chlormezanone, orphenadrine, orphenadrine/paracetamol and placebo in the treatment of painful skeletal muscle spasms. Ann Clin Res 1975; 7: 85-8
24. Hough LB, Nalwalk JW, Svokos K, et al. Pain-relieving drugs and the brain histaminergic system: multiple analgesic mechanisms from histamine, improgan and cimetidine. Inflamm Res 2004; 53 Suppl. 1: S43-4
25. Kashiba H, Fukui H, Senba E. Histamine H1 receptor mRNA is expressed in capsaicin-insensitive sensory neurons with neuropeptide Y-immunoreactivity in guinea pigs. Brain Res 2001; 901: 85-93
26. Diamond BI, Bluhm RE, Borison RL, et al. Brain histamine: an endogenous system for mediating pain [abstract]? Anaesthesiology 1981; 55: A286
27. Eguiagaray JG, Egea J, Bravo-Cordero JJ, et al. Neurotransmisores, senales de calcio y comunication neuronal [Neurotransmitters, calcium signalling and neuronal communication]. Neurocirugia 2004; 15: 109-18
28. Vane JR, Bahlke YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120
29. Pinardi G, Sierralta F, Miranda HF. Adrenergic mechanisms in antinociceptive effects of non steroidal anti-inflammatory drugs in acute thermal nociception in mice. Inflamm Res 2002; 51: 219-22
30. Pinardi G, Sierralta F, Miranda HF. Atropine reverses the antinociception of nonsteroidal anti-inflammatory drugs in the tail-flick test of mice. Pharmacol Biochem Behav 2003; 74: 603-8
31. Kornhuber J, Parsons CG, Hartmann S, et al. Orphenadrine is an uncompetitive n-methyl-d-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect 1995; 102: 237-42
32. Rumore MM, Schlichting DA. Analgesic effects of antihistamines. Life Sci 1985; 36: 403-16
33. Pubill D, Canudas AM, Pallas M, et al. Assessment of the adrenergic effects of orphenadrine in rat vas deferens. J Pharm Pharmacol 1999; 51: 307-12
34. Seibel K, Schaffler K, Reeh P, et al. Comparison of two different preparations of ibuprofen with regard to the time course of their analgesic effect: using laser somatosensory evoked potentials from UV-irritated skin in healthy volunteers. Drug Res 2004; 54: 444-51